Get the Stockscreener App
67.62
0.63%
0.42
After Hours:
67.83
0.21
+0.31%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $67.62, with a volume of 2.53M.
It is up +0.63% in the last 24 hours and down -10.10% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$67.20
Open:
$67.33
24h Volume:
2.53M
Relative Volume:
0.49
Market Cap:
$209.66B
Revenue:
$51.21B
Net Income/Loss:
$6.50B
P/E Ratio:
34.15
EPS:
1.98
Net Cash Flow:
$6.76B
1W Performance:
+3.03%
1M Performance:
-10.10%
6M Performance:
-11.12%
1Y Performance:
+5.46%
1-Day Range:
$67.14
$67.72
1-Week Range:
$65.86
$67.72
52-Week Range:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
67.62 | 209.66B | 51.21B | 6.50B | 6.76B | 2.085 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Why AstraZeneca PLC (AZN) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance
Healthcare of Ontario Pension Plan Trust Fund Purchases 58,970 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
D.A. Davidson & CO. Trims Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC ADR rises Friday, still underperforms market - MarketWatch
Top Stock Reports for Chevron, AstraZeneca & Arista Networks - Yahoo Finance
AstraZeneca rises Friday, outperforms market - MarketWatch
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Townsquare Capital LLC Increases Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca rises Thursday, outperforms market - MarketWatch
Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report - GlobeNewswire Inc.
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe - Seeking Alpha
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch - MSN
AstraZeneca's Enhertu breast cancer drug added to China's state insurance list - Reuters.com
AstraZeneca's Enhertu included in China's state insurance reimbursement - Marketscreener.com
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe - Bloomberg
AstraZeneca asthma drug more effective during attack than steroids, study finds - Reuters
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
AstraZeneca rises Wednesday, outperforms market - MarketWatch
Fmr LLC Increases Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Daiwa Securities Group Inc. Has $4.32 Million Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study - Yahoo Finance
Failure of AstraZeneca’s AZD4041 a blow for non-opioid OUD treatments - Yahoo Finance
Stock Watch: Investors Baulk At AstraZeneca And Bayer Q3 Updates - Citeline
Principal Street Partners LLC Purchases 8,986 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Sanders Capital LLC Has $1.17 Billion Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Quantbot Technologies LP Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Bank of Montreal Can Increases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Harvest Fund Management Co. Ltd Buys 9,203 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Cerity Partners LLC Has $15.54 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca reports results from trial of combination therapy for prostate cancer - Clinical Trials Arena
Thrivent Financial for Lutherans Cuts Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC Announces Positive High-Level Results from the Capitello-281 Phase III Trial - Marketscreener.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLCAZN - PR Newswire
AstraZeneca reports positive Phase 3 results for Truqap in prostate cancer (NASDAQ:AZN) - Seeking Alpha
AstraZeneca PLC (NASDAQ:AZN) Focuses on Growth in the U.S.: Is It the Best Time to Invest In AZN? - Insider Monkey
AstraZeneca remains steady Monday, underperforms market - MarketWatch
AstraZeneca’s Truqap Hits In Prostate Cancer - Citeline
AstraZeneca reports progress in prostate cancer treatment - Investing.com India
GCAR and AstraZeneca execute agreement to evaluate AZD1390 for glioblastoma - Clinical Trials Arena
AstraZeneca PLC (NASDAQ:AZN) Shares Bought by DRW Securities LLC - MarketBeat
Fisher Asset Management LLC Purchases 524,175 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Charles Schwab Investment Management Inc. Buys 8,830 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (AZN): Among the Most Promising Cancer Stocks According to Hedge Funds - MSN
AstraZeneca reports positive results from prostate cancer trial - ShareCast
AstraZeneca prostate cancer drug shows promising phase III results - Proactive Investors UK
Nwam LLC Buys Shares of 8,047 AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand - Yahoo Finance
Raymond James Trust N.A. Sells 11,239 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Eagle Asset Management Inc. - MarketBeat
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):